Close Menu

RNAi Still Has Far to Go

Premium

RNA interference has generated great excitement within the global research community as well as the biotech business sector due to its potential applications in functional genomics, drug screening, target validation, and therapeutic development. I have no doubt that within 10 years RNAi will emerge as a routine technique to study the problems in biomolecular medicine and potentially to treat diseases. But there is much to understand about the technology before that happens.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.